Edward Cliff, Haematology Registrar at Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, shared a post on LinkedIn:
“Excited to finally share our article chronicling the history and development of ibrutinib, a transformative and paradigm-shifting drug for chronic lymphocytic leukaemia and other B-cell malignancies.
What started out as a test compound for a hypothesis about rheumatoid arthritis, got thrown in as a side to a deal from one biotech to another as part of a fire sale, had early phase testing in dogs with lymphoma, and almost got quashed because it led to lymphocytosis in patients, ended up a highly effective, commercially successful drug.
A worthwhile read for anyone interested in drug discovery and development.
Congrats to Liam (now at Yale Law School despite my attempts to persuade him to study medicine) for leading this great work.”
Title: Discovering a transformative cancer drug: the case of ibrutinib
Authors: Liam Bendicksen, Lawrence King, Edward R. Scheffer Cliff, Aaron S. Kesselheim
Read the Full Article.
More posts featuring Edward Cliff.